KRAS and thyroid cancer: Our findings contrast with a recent report showing a positive correlation between a KRAS or BRAF mutation and clinical aggressiveness in colorectal, non-small-cell lung, and thyroid cancers (Lievre et al, 2006; Lee et al, 2007; Massarelli et al, 2007).